NCT02066909 - A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Healthy

Interventions

DRUG

0.15 mg PF-06649751

Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.

DRUG

0.5 mg PF-06649751

Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.

DRUG

0.5 mg PF-06649751

Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.

DRUG

1.5 mg PF-06649751

Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.

DRUG

1.5 mg PF-06649751 21 Days

Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.

DRUG

3.0 mg PF-06649751

Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.

DRUG

5.0 mg PF-06649751

Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.

DRUG

8.0 mg PF-06649751

Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.

DRUG

1.5 mg PF-06649751 in healthy Japanese subjects

Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.

Trial Locations (1)

New Haven Clinical Research Unit, New Haven